

Jakub Fichna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6435858/publications.pdf>

Version: 2024-02-01

308
papers

7,335
citations

71102

41
h-index

98798

67
g-index

318
all docs

318
docs citations

318
times ranked

9174
citing authors

#	ARTICLE	IF	CITATIONS
1	Lactoferrin: an overview of its main functions, immunomodulatory and antimicrobial role, and clinical significance. <i>Critical Reviews in Food Science and Nutrition</i> , 2022, 62, 6016-6033.	10.3	52
2	Adipocyte Fatty Acid Binding Protein (A-FABP) as a Potential New Therapeutic Target for the Treatment of Obesity - Associated Cancers. <i>Current Drug Targets</i> , 2022, 23, 597-605.	2.1	2
3	Fatty acids from natural resources in inflammatory gastrointestinal diseases with specific focus on inflammatory bowel disease. , 2022, , 121-135.		0
4	Positive allosteric modulation of endogenous delta opioid receptor signaling in the enteric nervous system is a potential treatment for gastrointestinal motility disorders. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 322, G66-G78.	3.4	7
5	Gold (III) Derivatives in Colon Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 724.	4.1	22
6	The Anti-Inflammatory Effect of Acidic Mammalian Chitinase Inhibitor OAT-177 in DSS-Induced Mouse Model of Colitis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2159.	4.1	3
7	Mast Cells Tryptase Promotes Intestinal Fibrosis in Natural Decellularized Intestinal Scaffolds. <i>Tissue Engineering and Regenerative Medicine</i> , 2022, 19, 717-726.	3.7	1
8	The Involvement of the Endogenous Opioid System in the Gastrointestinal Aging in Mice and Humans. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3565.	4.1	2
9	Preventing Bacterial Translocation in Patients with Leaky Gut Syndrome: Nutrition and Pharmacological Treatment Options. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3204.	4.1	21
10	Characterization of Specific Signatures of the Oral Cavity, Sputum, and Ileum Microbiota in Patients With Crohn's Disease. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 864944.	3.9	7
11	Oxygen Binding by Co(II) Complexes with Oxime-Containing Schiff Bases in Solution. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5492.	4.1	1
12	The GPR35 expression pattern is associated with overall survival in male patients with colorectal cancer. <i>Pharmacological Reports</i> , 2022, 74, 709-717.	3.3	4
13	The Nrf2 in the pathophysiology of the intestine: Molecular mechanisms and therapeutic implications for inflammatory bowel diseases. <i>Pharmacological Research</i> , 2021, 163, 105243.	7.1	81
14	Supplementation of Bovine Colostrum in Inflammatory Bowel Disease: Benefits and Contraindications. <i>Advances in Nutrition</i> , 2021, 12, 533-545.	6.4	16
15	Management of pain in colorectal cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103122.	4.4	19
16	Novel selective agonist of GPR18, PSB-1415 exerts potent anti-inflammatory and anti-nociceptive activities in animal models of intestinal inflammation and inflammatory pain. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14003.	3.0	15
17	Anti-inflammatory and antibacterial effects of human cathelicidin active fragment KR-12 in the mouse models of colitis: a novel potential therapy of inflammatory bowel diseases. <i>Pharmacological Reports</i> , 2021, 73, 163-171.	3.3	5
18	New insights into molecular pathways in colorectal cancer: Adiponectin, interleukin-6 and opioid signaling. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188460.	7.4	17

#	ARTICLE	IF	CITATIONS
19	Brain-derived neurotrophic factor is elevated in the blood serum of Crohn's disease patients, but is not influenced by anti-TNF α treatment: A pilot study. <i>Neurogastroenterology and Motility</i> , 2021, 33, e13978.	3.0	19
20	The age-related alterations in the enteric nervous system and their impact on peristalsis of the gastrointestinal tract. <i>Postepy Biochemii</i> , 2021, 67, 34-43.	0.2	1
21	Current concepts in the pathogenesis of cryptoglandular perianal fistula. <i>Journal of International Medical Research</i> , 2021, 49, 030006052098666.	1.0	30
22	The 25(OH)D ₃ , but Not 1,25(OH) ₂ D ₃ Levels Are Elevated in IBD Patients Regardless of Vitamin D Supplementation and Do Not Associate with Pain Severity or Frequency. <i>Pharmaceuticals</i> , 2021, 14, 284.	3.8	3
23	New Class of Anti-Inflammatory Therapeutics Based on Gold (III) Complexes in Intestinal Inflammation—Proof of Concept Based on In Vitro and In Vivo Studies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3121.	4.1	8
24	Current Overview on Clinical Management of Chronic Constipation. <i>Journal of Clinical Medicine</i> , 2021, 10, 1738.	2.4	26
25	Blockade of fructose transporter protein GLUT5 inhibits proliferation of colon cancer cells: proof of concept for a new class of anti-tumor therapeutics. <i>Pharmacological Reports</i> , 2021, 73, 939-945.	3.3	11
26	Changes in Fatty Acid Dietary Profile Affect the Brain-Gut Axis Functions of Healthy Young Adult Rats in a Sex-Dependent Manner. <i>Nutrients</i> , 2021, 13, 1864.	4.1	4
27	AdipoRon, an Orally Active, Synthetic Agonist of AdipoR1 and AdipoR2 Receptors Has Gastroprotective Effect in Experimentally Induced Gastric Ulcers in Mice. <i>Molecules</i> , 2021, 26, 2946.	3.8	10
28	Biomarkers for early detection of pancreatic cancer — miRNAs as a potential diagnostic and therapeutic tool?. <i>Cancer Biology and Therapy</i> , 2021, 22, 347-356.	3.4	15
29	Critical interactions between opioid and cannabinoid receptors during tolerance and physical dependence development to opioids in the murine gastrointestinal tract: proof of concept. <i>Pharmacological Reports</i> , 2021, 73, 1147-1154.	3.3	1
30	Chitinases and Chitinase-Like Proteins as Therapeutic Targets in Inflammatory Diseases, with a Special Focus on Inflammatory Bowel Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6966.	4.1	24
31	Oxidative Stress Does Not Influence Subjective Pain Sensation in Inflammatory Bowel Disease Patients. <i>Antioxidants</i> , 2021, 10, 1237.	5.1	8
32	Chlorogenic acid reduces inflammation in murine model of acute pancreatitis. <i>Pharmacological Reports</i> , 2021, 73, 1448-1456.	3.3	3
33	Activation of Free Fatty Acid Receptor 4 Affects Intestinal Inflammation and Improves Colon Permeability in Mice. <i>Nutrients</i> , 2021, 13, 2716.	4.1	12
34	Colonic inflammation induces changes in glucose levels through modulation of incretin system. <i>Pharmacological Reports</i> , 2021, 73, 1670-1679.	3.3	3
35	Chee Butter from Bovine Colostrum Reduces Inflammation in the Mouse Model of Acute Pancreatitis with Potential Involvement of Free Fatty Acid Receptors. <i>Nutrients</i> , 2021, 13, 3271.	4.1	1
36	Assessment of dietary habits in inflammatory bowel disease patients: A cross-sectional study from Poland. <i>Nutrition Bulletin</i> , 2021, 46, 432-442.	1.8	1

#	ARTICLE	IF	CITATIONS
37	The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders. <i>Pharmacological Research</i> , 2021, 172, 105840.	7.1	201
38	The role of fatty acids in Crohn's disease pathophysiology – An overview. <i>Molecular and Cellular Endocrinology</i> , 2021, 538, 111448.	3.2	16
39	IBS-Symptoms in IBD Patients – Manifestation of Concomitant or Different Entities. <i>Journal of Clinical Medicine</i> , 2021, 10, 31.	2.4	16
40	Current Overview on the Use of Mesenchymal Stem Cells for Perianal Fistula Treatment in Patients with Crohn's Disease. <i>Life</i> , 2021, 11, 1133.	2.4	4
41	Serum Levels of Chemerin in Patients with Inflammatory Bowel Disease as an Indicator of Anti-TNF Treatment Efficacy. <i>Journal of Clinical Medicine</i> , 2021, 10, 4615.	2.4	3
42	The association of the quality of sleep with proinflammatory cytokine profile in inflammatory bowel disease patients. <i>Pharmacological Reports</i> , 2021, 73, 1660-1669.	3.3	9
43	Characterization of the Synergistic Effect between Ligands of Opioid and Free Fatty Acid Receptors in the Mouse Model of Colitis. <i>Molecules</i> , 2021, 26, 6827.	3.8	2
44	Experimental therapies in Irritable Bowel Syndrome. <i>Folia Medica Cracoviensia</i> , 2021, 61, 5-17.	0.3	0
45	Association between brain-derived neurotrophic factor and symptoms of insomnia and depression in inflammatory bowel disease (IBD) patients. <i>European Psychiatry</i> , 2021, 64, S554-S554.	0.2	2
46	Protease-Activated Receptors – Key Regulators of Inflammatory Bowel Diseases Progression. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 7487-7497.	3.5	4
47	Current approach to hepatobiliary manifestations in inflammatory bowel disease.. <i>Journal of Physiology and Pharmacology</i> , 2021, 72, .	1.1	2
48	Endocannabinoid System. , 2020, , 159-166.		0
49	Chain length of dietary fatty acids determines gastrointestinal motility and visceromotor function in mice in a fatty acid binding protein 4-dependent manner. <i>European Journal of Nutrition</i> , 2020, 59, 2481-2496.	3.9	4
50	Recent advances in the pharmacological management of constipation predominant irritable bowel syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 73-84.	1.8	9
51	Free Fatty Acid Receptors as new potential therapeutic target in inflammatory bowel diseases. <i>Pharmacological Research</i> , 2020, 152, 104604.	7.1	35
52	Recent advances in inflammatory bowel disease therapy. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 155, 105550.	4.0	9
53	What role do cannabinoids have in modern medicine as gastrointestinal anti-inflammatory drugs?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1931-1934.	1.8	2
54	Cyclic derivative of morphiceptin Dmt-cyclo-(D-Lys-Phe-D-Pro-Asp)-NH ₂ (P-317), a mixed agonist of MOP and KOP opioid receptors, exerts anti-inflammatory and anti-tumor activity in colitis and colitis-associated colorectal cancer in mice. <i>European Journal of Pharmacology</i> , 2020, 885, 173463.	3.5	6

#	ARTICLE	IF	CITATIONS
55	Traditional Chinese Medicine Da-Cheng-Qi-Tang Ameliorates Impaired Gastrointestinal Motility and Intestinal Inflammatory Response in a Mouse Model of Postoperative Ileus. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-12.	1.2	1
56	Expression of FFAR3 and FFAR4 Is Increased in Gastroesophageal Reflux Disease. Journal of Clinical Medicine, 2020, 9, 4111.	2.4	5
57	Anti-Inflammatory Effect of Homo- and Heterodimers of Natural Enkephalinase Inhibitors in Experimental Colitis in Mice. Molecules, 2020, 25, 5820.	3.8	6
58	Air Pollution Associates with Cancer Incidences in Poland. Applied Sciences (Switzerland), 2020, 10, 7489.	2.5	6
59	Walnut Oil Alleviates Intestinal Inflammation and Restores Intestinal Barrier Function in Mice. Nutrients, 2020, 12, 1302.	4.1	23
60	Silver nanoparticles based on blackcurrant extract show potent anti-inflammatory effect in vitro and in DSS-induced colitis in mice. International Journal of Pharmaceutics, 2020, 585, 119549.	5.2	21
61	Nrf2 transcriptional activity in the mouse affects the physiological response to tribromoethanol. Biomedicine and Pharmacotherapy, 2020, 128, 110317.	5.6	4
62	Circadian rhythm abnormalities in patients with inflammatory bowel disease – association with adipokine profile. Scandinavian Journal of Gastroenterology, 2020, 55, 294-300.	1.5	10
63	Cyclic derivatives of morphiceptin possess anti-transit effect in the gastrointestinal tract and alleviate abdominal pain in mice. Pharmacological Reports, 2020, 72, 314-321.	3.3	3
64	Chemerin in immune response and gastrointestinal pathophysiology. Clinica Chimica Acta, 2020, 504, 146-153.	1.1	22
65	Opioids in Cancer Development, Progression and Metastasis: Focus on Colorectal Cancer. Current Treatment Options in Oncology, 2020, 21, 6.	3.0	23
66	Desensitization of transient receptor potential vanilloid type-1 (TRPV1) channel as promising therapy of irritable bowel syndrome: characterization of the action of palvanil in the mouse gastrointestinal tract. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 1357-1364.	3.0	12
67	Visualization of Estrogen Receptors in Colons of Mice with TNBS-Induced Crohn's Disease using Immunofluorescence. Journal of Visualized Experiments, 2020, , .	0.3	1
68	G Protein-Coupled Receptor 30 (GPR30) Expression Pattern in Inflammatory Bowel Disease Patients Suggests its Key Role in the Inflammatory Process. A Preliminary Study. Journal of Gastrointestinal and Liver Diseases, 2020, 26, 29-35.	0.9	26
69	Free Fatty Acid Receptors as New Potential Targets in Colorectal Cancer. Current Drug Targets, 2020, 21, 1397-1404.	2.1	7
70	Spent hops (<i>Humulus Lupulus</i> L.) extract as modulator of the inflammatory response in lipopolysaccharide stimulated RAW 264.7 macrophages. Journal of Physiology and Pharmacology, 2020, 71, .	1.1	7
71	Psychological stress – does it affect wound healing?. Forum Leczenia Ran, 2020, 2, 95-101.	0.0	0
72	Biologic Therapy in Crohn's Disease – What We Have Learnt So Far. Current Drug Targets, 2020, 21, 792-806.	2.1	2

#	ARTICLE	IF	CITATIONS
73	Biomarkers for Early Detection of Colitis-associated Colorectal Cancer - Current Concepts, Future Trends. <i>Current Drug Targets</i> , 2020, 22, 137-145.	2.1	5
74	Inflammatory Bowel Disease – From Bench to Bedside. <i>Current Drug Targets</i> , 2020, 21, 1396-1396.	2.1	2
75	Single Nucleotide Polymorphisms in Colitis-Associated Colorectal Cancer: A Current Overview with Emphasis on the Role of the Associated Genes Products. <i>Current Drug Targets</i> , 2020, 21, 1456-1462.	2.1	1
76	Japanese quince (<i>Chaenomeles japonica</i>) leaf phenol extract as modulator of the inflammatory response in lipopolysaccharide-triggered murine macrophage RAW 264.7 cells. <i>Journal of Physiology and Pharmacology</i> , 2020, 71, .	1.1	2
77	Enkephalin degradation in serum of patients with inflammatory bowel diseases. <i>Pharmacological Reports</i> , 2019, 71, 42-47.	3.3	5
78	1-Substituted sialorphin analogues synthesis, molecular modelling and in vitro effect on enkephalins degradation by NEP. <i>Amino Acids</i> , 2019, 51, 1201-1207.	2.7	6
79	Role of glucagon-like peptides in inflammatory bowel diseases – current knowledge and future perspectives. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2019, 392, 1321-1330.	3.0	27
80	Dietary fatty acid content influences the expression of genes involved in the lipid turnover and inflammation in mouse colon and spleen. <i>Pharmacological Reports</i> , 2019, 71, 899-908.	3.3	4
81	Sex- and Age-Related Estrogen Signaling Alteration in Inflammatory Bowel Diseases: Modulatory Role of Estrogen Receptors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3175.	4.1	29
82	Organometallic Compounds and Metal Complexes in Current and Future Treatments of Inflammatory Bowel Disease and Colorectal Cancer – a Critical Review. <i>Biomolecules</i> , 2019, 9, 398.	4.0	12
83	Gut microbiota: what is its place in pharmacology?. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 921-930.	3.1	11
84	Changes in the diet composition of fatty acids and fiber affect the lower gastrointestinal motility but have no impact on cardiovascular parameters: In vivo and in vitro studies. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13651.	3.0	7
85	G protein-coupled estrogen receptor mediates anti-inflammatory action in Crohn's disease. <i>Scientific Reports</i> , 2019, 9, 6749.	3.3	29
86	Effectiveness and therapeutic value of phytochemicals in acute pancreatitis: A review. <i>Pancreatology</i> , 2019, 19, 481-487.	1.1	21
87	Possible application of trefoil factor family peptides in gastroesophageal reflux and Barrett's esophagus. <i>Peptides</i> , 2019, 115, 27-31.	2.4	3
88	P706 Patient knowledge towards biological treatment in inflammatory bowel diseases: a cross-sectional survey. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S474-S474.	1.3	0
89	Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13526.	3.0	11
90	Focus on current and future management possibilities in inflammatory bowel disease-related chronic pain. <i>International Journal of Colorectal Disease</i> , 2019, 34, 217-227.	2.2	39

#	ARTICLE	IF	CITATIONS
91	Alterations of colonic sensitivity and gastric dysmotility after acute cisplatin and granisetron. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13499.	3.0	14
92	Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system. <i>Biochemical Pharmacology</i> , 2019, 161, 37-51.	4.4	22
93	High activity of endogenous opioid system protects against gastric damage development in mouse models of gastric mucosal injury. <i>Pharmacological Reports</i> , 2019, 71, 218-224.	3.3	8
94	The role of adipose tissue in the pathogenesis of Crohn's disease. <i>Pharmacological Reports</i> , 2019, 71, 105-111.	3.3	13
95	Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 473-481.	0.9	6
96	Evaluation of the effect of liposomes loaded with chlorogenic acid in treatment of 2,4,6-trinitrobenzenesulfonic acid-induced murine colitis. <i>Journal of Physiology and Pharmacology</i> , 2019, 70, .	1.1	2
97	Response to lubiprostone in chronic constipation is associated with increased mucus and mucin output: a randomized clinical trial. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 263-264.	0.9	0
98	Comparison of the efficacy of available statistical methods for prediction of the hospitalizations number: proof of concept and validation based on the analysis of Polish National Health Fund data in the years 2009-2017. <i>Folia Medica Cracoviensia</i> , 2019, 59, 89-100.	0.3	0
99	The place of tachykinin NK2 receptor antagonists in the treatment diarrhea-predominant irritable bowel syndrome. <i>Journal of Physiology and Pharmacology</i> , 2019, 70, .	1.1	5
100	Antinociceptive potency of a fluorinated cyclopeptide Dmt-c[D-Lys-Phe- <i>p</i> -CF ₃ -Phe-Asp]NH ₂ . <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2018, 33, 560-566.	5.2	8
101	Antinociceptive potency of enkephalins and enkephalinase inhibitors in the mouse model of colorectal distension – proof of concept. <i>Chemical Biology and Drug Design</i> , 2018, 92, 1387-1392.	3.2	7
102	Novel derivatives of 1,2,3-triazole, cannabinoid-1 receptor ligands modulate gastrointestinal motility in mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 435-444.	3.0	3
103	The mechanisms linking obesity to colon cancer: An overview. <i>Obesity Research and Clinical Practice</i> , 2018, 12, 251-259.	1.8	60
104	FABP4 blocker attenuates colonic hypomotility and modulates white adipose tissue-derived hormone levels in mouse models mimicking constipation-predominant IBS. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13272.	3.0	8
105	Alterations in the gut barrier and involvement of Toll-like receptor 4 in murine postoperative ileus. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13286.	3.0	9
106	Prosecretory effect of loperamide in ileal and colonic mucosae of mice displaying high or low swim stress-induced analgesia associated with high and low endogenous opioid system activity. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13166.	3.0	1
107	Development of the rectal dosage form with silver-coated glass beads for local-action applications in lower sections of the gastrointestinal tract. <i>Pharmaceutical Development and Technology</i> , 2018, 23, 295-300.	2.4	4
108	Estrogen signaling deregulation related with local immune response modulation in irritable bowel syndrome. <i>Molecular and Cellular Endocrinology</i> , 2018, 471, 89-96.	3.2	31

#	ARTICLE	IF	CITATIONS
109	Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer. <i>Current Drug Targets</i> , 2018, 19, 1731-1737.	2.1	12
110	One step ahead: miRNA-34 in colon cancer-future diagnostic and therapeutic tool?. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 1-8.	4.4	19
111	Young GI angle: My biggest (career) mistake. <i>United European Gastroenterology Journal</i> , 2018, 6, 1278-1279.	3.8	0
112	Novel peptide inhibitor of dipeptidyl peptidase IV (Tyr-Pro-D-Ala-NH ₂) with anti-inflammatory activity in the mouse models of colitis. <i>Peptides</i> , 2018, 108, 34-45.	2.4	25
113	Diagnostic value of chemerin in lower gastrointestinal diseases—a review. <i>Peptides</i> , 2018, 108, 19-24.	2.4	6
114	Chronic abdominal pain in irritable bowel syndrome — current and future therapies. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 729-739.	3.1	13
115	Triphala: current applications and new perspectives on the treatment of functional gastrointestinal disorders. <i>Chinese Medicine</i> , 2018, 13, 39.	4.0	39
116	Evaluation of Melatonin Secretion and Metabolism Exponents in Patients with Ulcerative and Lymphocytic Colitis. <i>Molecules</i> , 2018, 23, 272.	3.8	12
117	Alanine scan of sialorphin and its hybrids with opiorphin: synthesis, molecular modelling and effect on enkephalins degradation. <i>Amino Acids</i> , 2018, 50, 1083-1088.	2.7	9
118	Inflammation-associated changes in DOR expression and function in the mouse colon. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, G544-G559.	3.4	20
119	The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. <i>European Journal of Pharmacology</i> , 2018, 836, 34-43.	3.5	9
120	Bile acids and FXR in functional gastrointestinal disorders. <i>Digestive and Liver Disease</i> , 2018, 50, 795-803.	0.9	16
121	Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A Review. <i>Current Drug Targets</i> , 2018, 19, 1774-1781.	2.1	25
122	New Trends in Liposome-based Drug Delivery in Colorectal Cancer. <i>Mini-Reviews in Medicinal Chemistry</i> , 2018, 19, 3-11.	2.4	21
123	The effect of long-term melatonin supplementation on psychosomatic disorders in postmenopausal women. <i>Journal of Physiology and Pharmacology</i> , 2018, 69, .	1.1	6
124	Pharmacological and dietary factors in prevention of colorectal cancer. <i>Journal of Physiology and Pharmacology</i> , 2018, 69, .	1.1	23
125	Sleep disturbance and disease activity in adult patients with inflammatory bowel diseases. <i>Journal of Physiology and Pharmacology</i> , 2018, 69, .	1.1	10
126	High activity of the endogenous opioid system and acute but not chronic stress influence experimental colitis development in mice. <i>Journal of Physiology and Pharmacology</i> , 2018, 69, .	1.1	2

#	ARTICLE	IF	CITATIONS
127	Evaluation of anti-inflammatory effect of silver-coated glass beads in mice with experimentally induced colitis as a new type of treatment in inflammatory bowel disease. <i>Pharmacological Reports</i> , 2017, 69, 386-392.	3.3	19
128	G protein-coupled receptor 55 (GPR55) expresses differently in patients with Crohn's disease and ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 711-715.	1.5	12
129	Cannabinoids as gastrointestinal anti-inflammatory drugs. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13038.	3.0	12
130	G protein-coupled estrogen receptor and estrogen receptor ligands regulate colonic motility and visceral pain. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13025.	3.0	55
131	Serum Cyclophilin A Correlates with Increased Tissue MMP-9 in Patients with Ulcerative Colitis, but Not with Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1511-1517.	2.3	16
132	Systemic Administration of Sialorphan Attenuates Experimental Colitis in Mice via Interaction With Mu and Kappa Opioid Receptors. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 988-998.	1.3	17
133	Cannabinoid Receptor Type 1 and mu-Opioid Receptor Polymorphisms Are Associated With Cyclic Vomiting Syndrome. <i>American Journal of Gastroenterology</i> , 2017, 112, 933-939.	0.4	42
134	Methyl-orvinolol Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome. <i>Pharmacological Reports</i> , 2017, 69, 350-357.	3.3	9
135	The Anti-Inflammatory Effect and Intestinal Barrier Protection of HU210 Differentially Depend on TLR4 Signaling in Dextran Sulfate Sodium-Induced Murine Colitis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 372-386.	2.3	23
136	Inhibition of nuclear factor-kappaB, cyclooxygenase-2, and metalloproteinase-9 expression by flavanols from evening primrose (<i>Oenothera paradoxa</i>) in human colon cancer SW-480 cells. <i>Journal of Functional Foods</i> , 2017, 37, 553-563.	3.4	11
137	Fat-soluble Vitamin Deficiencies and Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 878-889.	2.2	61
138	Highly selective CB2 receptor agonist A836339 has gastroprotective effect on experimentally induced gastric ulcers in mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 1015-1027.	3.0	14
139	New Peptide Inhibitor of Dipeptidyl Peptidase IV, EMD8-1 Extends the Half-Life of GLP-2 and Attenuates Colitis in Mice after Topical Administration. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 363, 92-103.	2.5	24
140	Targeting fatty acid amide hydrolase and transient receptor potential vanilloid 1 simultaneously to modulate colonic motility and visceral sensation in the mouse: A pharmacological intervention with N-arachidonoylserotonin (AA5-HT). <i>Neurogastroenterology and Motility</i> , 2017, 29, e13148.	3.0	10
141	Synthesis and evaluation of anti-inflammatory properties of silver nanoparticle suspensions in experimental colitis in mice. <i>Chemical Biology and Drug Design</i> , 2017, 89, 538-547.	3.2	37
142	Young GI angle: The role of bibliometrics in scientist's career development. <i>United European Gastroenterology Journal</i> , 2017, 5, 1151-1152.	3.8	2
143	Dual Functional Capability of Dendritic Cells as Cytokine-Induced Killer Cells in Improving Side Effects of Colorectal Cancer Therapy. <i>Frontiers in Pharmacology</i> , 2017, 8, 126.	3.5	15
144	Cannabinoids and Effects on the Gastrointestinal Tract: A Focus on Motility. , 2017, , 947-957.		6

#	ARTICLE	IF	CITATIONS
145	Targeting Histamine Receptors in Irritable Bowel Syndrome: A Critical Appraisal. <i>Journal of Neurogastroenterology and Motility</i> , 2017, 23, 341-348.	2.4	34
146	Fatty acid amide hydrolase (FAAH) inhibitor PF-3845 reduces viability, migration and invasiveness of human colon adenocarcinoma Colo-205 cell line: an in vitro study. <i>Acta Biochimica Polonica</i> , 2017, 64, 519-525.	0.5	33
147	Future Treatment of Constipation-associated Disorders: Role of Relamorelin and Other Ghrelin Receptor Agonists. <i>Journal of Neurogastroenterology and Motility</i> , 2017, 23, 171-179.	2.4	17
148	The Role of Oxidative Stress in the Pathophysiology of Gastrointestinal Disorders. , 2017, , 53-64.		1
149	Cannabis and Cannabinoids and the Effects on Gastrointestinal Function: An Overview. , 2017, , 471-480.		5
150	Flavanols from Japanese quince (<i>Chaenomeles japonica</i>) fruit suppress expression of cyclooxygenase-2, metalloproteinase-9, and nuclear factor- κ B in human colon cancer cells. <i>Acta Biochimica Polonica</i> , 2017, 64, 567-576.	0.5	29
151	Modulation of the endocannabinoid system by the fatty acid amide hydrolase, monoacylglycerol and diacylglycerol lipase inhibitors as an attractive target for secretory diarrhoea therapy. <i>Journal of Physiology and Pharmacology</i> , 2017, 68, 591-596.	1.1	5
152	Relamorelin and other ghrelin receptor agonists - future options for gastroparesis, functional dyspepsia and proton pump inhibitors-resistant non-erosive reflux disease. <i>Journal of Physiology and Pharmacology</i> , 2017, 68, 797-805.	1.1	11
153	Elevated risk of venous thromboembolic events in patients with inflammatory myopathies. <i>Vascular Health and Risk Management</i> , 2016, 12, 233.	2.3	11
154	Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 771.	2.0	13
155	Polyunsaturated Fatty Acids and Their Derivatives: Therapeutic Value for Inflammatory, Functional Gastrointestinal Disorders, and Colorectal Cancer. <i>Frontiers in Pharmacology</i> , 2016, 7, 459.	3.5	71
156	Expression and physiology of opioid receptors in the gastrointestinal tract. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 3-10.	2.3	34
157	The effect of opioid agonists and antagonists on gastrointestinal motility in mice selected for high and low swim stress-induced analgesia. <i>Neurogastroenterology and Motility</i> , 2016, 28, 175-185.	3.0	5
158	RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectives. <i>BioEssays</i> , 2016, 38, 344-354.	2.5	15
159	Anemia of Chronic Disease and Iron Deficiency Anemia in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1198-1208.	1.9	54
160	Is insulin-like growth factor 1 (IGF-1) system an attractive target inflammatory bowel diseases? Benefits and limitation of potential therapy. <i>Pharmacological Reports</i> , 2016, 68, 809-815.	3.3	12
161	Circadian rhythm abnormalities - Association with the course of inflammatory bowel disease. <i>Pharmacological Reports</i> , 2016, 68, 847-851.	3.3	28
162	Pharmacology and metabolism of infliximab biosimilars - A new treatment option in inflammatory bowel diseases. <i>Pharmacological Reports</i> , 2016, 68, 797-801.	3.3	3

#	ARTICLE	IF	CITATIONS
163	LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity. <i>Pharmacological Reports</i> , 2016, 68, 802-808.	3.3	117
164	Inflammatory bowel diseases and reproductive health. <i>Pharmacological Reports</i> , 2016, 68, 859-864.	3.3	7
165	Anticonvulsant activity of melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, in mice. <i>Behavioural Brain Research</i> , 2016, 307, 199-207.	2.2	15
166	The influence of lipoic acid on caveolin-1-regulated antioxidative enzymes in the mouse model of acute ulcerative colitis. <i>Biomedicine and Pharmacotherapy</i> , 2016, 84, 470-475.	5.6	25
167	Anti-inflammatory effect of novel analogs of natural enkephalinase inhibitors in a mouse model of experimental colitis. <i>Future Medicinal Chemistry</i> , 2016, 8, 2231-2243.	2.3	17
168	PhDs in academic gastroenterology: key to a successful career. <i>United European Gastroenterology Journal</i> , 2016, 4, 479-480.	3.8	0
169	Abnormal cannabidiol attenuates experimental colitis in mice, promotes wound healing and inhibits neutrophil recruitment. <i>Journal of Inflammation</i> , 2016, 13, 21.	3.4	25
170	Measurement of Silver Nanolayer Absorption by the Body in an in Vivo Model of Inflammatory Gastrointestinal Diseases. <i>Metrology and Measurement Systems</i> , 2016, 23, 133-142.	1.4	2
171	The influence of family pattern abnormalities in the early stages of life on the course of inflammatory bowel diseases. <i>Pharmacological Reports</i> , 2016, 68, 852-858.	3.3	7
172	Inflammatory bowel disease treatment. <i>Pharmacological Reports</i> , 2016, 68, 787-788.	3.3	4
173	Common links between metabolic syndrome and inflammatory bowel disease: Current overview and future perspectives. <i>Pharmacological Reports</i> , 2016, 68, 837-846.	3.3	43
174	Melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, attenuates TNBS-induced colitis in mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2016, 389, 511-519.	3.0	18
175	Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 275-286.	4.1	16
176	Mean Platelet Volume in Crohn's Disease Patients Predicts Sustained Response to a 52-Week Infliximab Therapy: A Pilot Study. <i>Digestive Diseases and Sciences</i> , 2016, 61, 542-549.	2.3	16
177	Enhancement of anticancer potential of polyphenols by covalent modifications. <i>Biochemical Pharmacology</i> , 2016, 109, 1-13.	4.4	27
178	Neuropharmacological characterization of the oneirogenic Mexican plant <i>Calea zacatechichi</i> aqueous extract in mice. <i>Metabolic Brain Disease</i> , 2016, 31, 631-641.	2.9	7
179	Mixed MOP/DOP agonist biphalin elicits anti-transit effect in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms. <i>Pharmacological Reports</i> , 2016, 68, 32-36.	3.3	11
180	Review: The Role of MOP and DOP Receptors in Treatment of Diarrheapredominant Irritable Bowel Syndrome. <i>Mini-Reviews in Medicinal Chemistry</i> , 2016, 16, 1462-1469.	2.4	6

#	ARTICLE	IF	CITATIONS
181	Alopecia areata in patients with inflammatory bowel disease: an overview. <i>Folia Medica Cracoviensia</i> , 2016, 56, 5-12.	0.3	3
182	Comment on Choi <i>et al.</i> : High-fat diet decreases energy expenditure and expression of genes controlling lipid metabolism, mitochondrial function and skeletal system development in the adipose tissue, along with increased expression of extracellular matrix remodelling- and inflammation-related genes. <i>British Journal of Nutrition</i> , 2015, 114, 497-498.	2.3	1
183	Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1057-1068.	3.0	14
184	Orally administered novel cyclic pentapeptide P-317 alleviates symptoms of diarrhoea-predominant irritable bowel syndrome. <i>Journal of Pharmacy and Pharmacology</i> , 2015, 67, 244-254.	2.4	20
185	Salvinorin A analogues PR-37 and PR-38 attenuate compound 48/80-induced itch responses in mice. <i>British Journal of Pharmacology</i> , 2015, 172, 4331-4341.	5.4	16
186	<i>In vitro</i> and non-invasive <i>in vivo</i> effects of the cannabinoid receptor agonist AM-841 on gastrointestinal motor function in the rat. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1721-1735.	3.0	24
187	A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome. <i>Phytotherapy Research</i> , 2015, 29, 1822-1827.	5.8	96
188	Role of Transient Receptor Potential Channels in Intestinal Inflammation and Visceral Pain. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 419-427.	1.9	50
189	Berberine Improves Intestinal Motility and Visceral Pain in the Mouse Models Mimicking Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Symptoms in an Opioid-Receptor Dependent Manner. <i>PLoS ONE</i> , 2015, 10, e0145556.	2.5	41
190	Editorial (Thematic Issue: The Link between Cardiovascular and Circulatory Events in Inflammatory) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	2.1	0
191	The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective. <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 278-284.	3.2	11
192	Beneficial Effects of Probiotics, Prebiotics, Synbiotics, and Psychobiotics in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1674-1682.	1.9	131
193	Transient receptor potential vanilloid 4 inhibits mouse colonic motility by activating NO-dependent enteric neurotransmission. <i>Journal of Molecular Medicine</i> , 2015, 93, 1297-1309.	3.9	31
194	Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1093-1099.	4.1	22
195	Calea zacatechichi dichloromethane extract exhibits antidiarrheal and antinociceptive effects in mouse models mimicking irritable bowel syndrome. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015, 388, 1069-1077.	3.0	19
196	Polyphenols as mitochondria-targeted anticancer drugs. <i>Cancer Letters</i> , 2015, 366, 141-149.	7.2	92
197	Orally available extract from <i>Brassica oleracea</i> var. <i>capitata rubra</i> attenuates experimental colitis in mouse models of inflammatory bowel diseases. <i>Journal of Functional Foods</i> , 2015, 17, 587-599.	3.4	35
198	Experimental colitis in mice is attenuated by topical administration of chlorogenic acid. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015, 388, 643-651.	3.0	58

#	ARTICLE	IF	CITATIONS
199	Role of G Protein-coupled Orphan Receptors in Intestinal Inflammation. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 666-673.	1.9	8
200	Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice. <i>European Journal of Pharmacology</i> , 2015, 765, 582-590.	3.5	19
201	The past, present and future of gastroenterology in Europe and worldwide. <i>United European Gastroenterology Journal</i> , 2015, 3, 217-217.	3.8	1
202	Encenicline, an $\alpha 7$ Nicotinic Acetylcholine Receptor Partial Agonist, Reduces Immune Cell Infiltration in the Colon and Improves Experimental Colitis in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 356, 157-169.	2.5	35
203	Cannabinoids Regulate Intestinal Motor Function and Electrophysiological Activity of Myocytes in Rodents. <i>Archives of Medical Research</i> , 2015, 46, 439-447.	3.3	1
204	Silver and Other Metals in the Treatment of Gastrointestinal Diseases. <i>Current Medicinal Chemistry</i> , 2015, 22, 3695-3706.	2.4	6
205	Prevention and Therapeutic Strategies of Thromboembolic Events in Patients with Inflammatory Bowel Diseases: A Report of Three Cases. <i>Current Drug Targets</i> , 2015, 16, 194-198.	2.1	5
206	Ischemic Colitis: Current Diagnosis and Treatment. <i>Current Drug Targets</i> , 2015, 16, 209-218.	2.1	16
207	Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases. <i>Current Drug Targets</i> , 2015, 16, 219-225.	2.1	11
208	Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation. <i>World Journal of Gastroenterology</i> , 2015, 21, 7436.	3.3	7
209	Role of environmental pollution in irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , 2015, 21, 11371.	3.3	23
210	Nociceptin effect on intestinal motility depends on opioid-receptor like-1 receptors and nitric oxide synthase co-localization. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2015, 6, 73.	1.1	6
211	Rhenium-coated glass beads for intracolonic administration attenuate TNBS-induced colitis in mice: Proof-of-Concept Study. <i>Folia Medica Cracoviensia</i> , 2015, 55, 49-57.	0.3	2
212	What is the Future of the Gut Microbiota-Related Treatment? Toward Modulation of Microbiota in Preventive and Therapeutic Medicine. <i>Frontiers in Medicine</i> , 2014, 1, 19.	2.6	8
213	Correlations between skin lesions induced by anti-tumor necrosis factor- α and selected cytokines in Crohn's disease patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 7019.	3.3	33
214	Comment on "Intestinal Inflammation Modulates Expression of the Iron-Regulating Hormone Hcpidin Depending on Erythropoietic Activity and the Commensal Microbiota". <i>Journal of Immunology</i> , 2014, 193, 5763.1-5763.	0.8	0
215	Activation of the endogenous nociceptin system by selective nociceptin receptor agonist SCH 221510 produces antitransit and antinociceptive effect: a novel strategy for treatment of diarrhea-predominant IBS. <i>Neurogastroenterology and Motility</i> , 2014, 26, 1539-1550.	3.0	16
216	Novel Orally Available Salvinorin A Analog PR-38 Inhibits Gastrointestinal Motility and Reduces Abdominal Pain in Mouse Models Mimicking Irritable Bowel Syndrome. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 350, 69-78.	2.5	31

#	ARTICLE	IF	CITATIONS
217	Effects of Berberine in the Gastrointestinal Tract – A Review of Actions and Therapeutic Implications. <i>The American Journal of Chinese Medicine</i> , 2014, 42, 1053-1070.	3.8	106
218	Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 52, 173-179.	4.0	34
219	Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides. <i>Neurogastroenterology and Motility</i> , 2014, 26, 470-481.	3.0	54
220	Novel orally available salvinorin A analog PR-38 protects against experimental colitis and reduces abdominal pain in mice by interaction with opioid and cannabinoid receptors. <i>Biochemical Pharmacology</i> , 2014, 92, 618-626.	4.4	28
221	Current overview of colitis-associated colorectal cancer. <i>Open Life Sciences</i> , 2014, 9, 1022-1029.	1.4	5
222	Antinociceptive and antidepressant-like action of endomorphin-2 analogs with proline surrogates in position 2. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 4803-4809.	3.0	13
223	Cross-talk between serotonin and cannabinoid signaling in the gut, new insights and future perspectives. <i>Pain</i> , 2014, 155, 2204-2205.	4.2	0
224	Polyphenol extract from evening primrose pomace alleviates experimental colitis after intracolonic and oral administration in mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014, 387, 1069-1078.	3.0	40
225	Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014, 387, 605-620.	3.0	288
226	Chinese Herbal Medicines in the Treatment of IBD and Colorectal Cancer: A Review. <i>Current Treatment Options in Oncology</i> , 2014, 15, 405-420.	3.0	87
227	Anti-Inflammatory and Antinociceptive Action of an Orally Available Nociceptin Receptor Agonist SCH 221510 in a Mouse Model of Inflammatory Bowel Diseases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 348, 401-409.	2.5	28
228	Anti-inflammatory and antinociceptive action of the dimeric enkephalin peptide biphalin in the mouse model of colitis: New potential treatment of abdominal pain associated with inflammatory bowel diseases. <i>Peptides</i> , 2014, 60, 102-106.	2.4	30
229	Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH). <i>Journal of Crohn's and Colitis</i> , 2014, 8, 998-1009.	1.3	85
230	P071 G protein-coupled receptor 30 expression in inflammatory bowel disease patients. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S92.	1.3	1
231	Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms. <i>European Journal of Pharmacology</i> , 2014, 736, 63-69.	3.5	25
232	Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases. <i>Pharmacological Reports</i> , 2014, 66, 766-775.	3.3	81
233	Anti-inflammatory action of a novel orally available peptide 317 in mouse models of inflammatory bowel diseases. <i>Pharmacological Reports</i> , 2014, 66, 741-750.	3.3	18
234	Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. <i>Journal of Gastroenterology</i> , 2014, 49, 24-45.	5.1	151

#	ARTICLE	IF	CITATIONS
235	Cannabinoids Alleviate Experimentally Induced Intestinal Inflammation by Acting at Central and Peripheral Receptors. <i>PLoS ONE</i> , 2014, 9, e109115.	2.5	59
236	Pharmacological Properties of Novel Cyclic Pentapeptides with μ -opioid Receptor Agonist Activity. <i>Medicinal Chemistry</i> , 2014, 10, 154-161.	1.5	9
237	Antinociceptive effects of novel melatonin receptor agonists in mouse models of abdominal pain. <i>World Journal of Gastroenterology</i> , 2014, 20, 1298.	3.3	18
238	Acid loading stimulates rat glomerular mesangial cells proliferation through Na ⁺ /H ⁺ exchanger isoform 1 (NHE1)-dependent pathway. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013, 386, 563-569.	3.0	6
239	Inhibition of proteases as a novel therapeutic strategy in the treatment of metabolic, inflammatory and functional diseases of the gastrointestinal tract. <i>Drug Discovery Today</i> , 2013, 18, 708-715.	6.4	25
240	Novel glycosylated endomorphin-2 analog produces potent centrally-mediated antinociception in mice after peripheral administration. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 6673-6676.	2.2	13
241	The cannabinoid CB1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice. <i>Neurogastroenterology and Motility</i> , 2013, 25, e550-9.	3.0	37
242	A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice. <i>Neuropharmacology</i> , 2013, 71, 255-263.	4.1	64
243	The μ -opioid receptor-selective peptide antagonists, antanal-1 and antanal-2, produce anticonvulsant effects in mice. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 40, 126-131.	4.8	9
244	Characterization of the effects of opiorphin and sialorphin and their analogs substituted in position 1 with pyroglutamic acid on motility in the mouse ileum. <i>Journal of Peptide Science</i> , 2013, 19, 166-172.	1.4	15
245	Synthesis and Opioid Activity of Novel 6-ketolevorphanol Derivatives. <i>Medicinal Chemistry</i> , 2013, 9, 1-10.	1.5	3
246	Endocannabinoid and Cannabinoid-Like Fatty Acid Amide Levels Correlate with Pain-Related Symptoms in Patients with IBS-D and IBS-C: A Pilot Study. <i>PLoS ONE</i> , 2013, 8, e85073.	2.5	45
247	Nociceptin / Orphanin FQ (NOP) Receptors as Novel Potential Target in the Treatment of Gastrointestinal Diseases. <i>Current Drug Targets</i> , 2013, 14, 1203-1209.	2.1	20
248	Transient Receptor Potential Vanilloid 4 blockade protects against experimental colitis in mice: a new strategy for inflammatory bowel diseases treatment?. <i>Neurogastroenterology and Motility</i> , 2012, 24, e557-60.	3.0	70
249	New neostigmine-based behavioral mouse model of abdominal pain. <i>Pharmacological Reports</i> , 2012, 64, 1146-1154.	3.3	11
250	Brain-Gut Interactions in IBS. <i>Frontiers in Pharmacology</i> , 2012, 3, 127.	3.5	99
251	Structural comparison of endomorphin-2 and its conformationally restricted analog. <i>Open Chemistry</i> , 2012, 10, 172-179.	1.9	0
252	Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors*. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1137-1145.	1.9	61

#	ARTICLE	IF	CITATIONS
253	Kinetic studies of novel inhibitors of endomorphin degrading enzymes. <i>Medicinal Chemistry Research</i> , 2012, 21, 1445-1450.	2.4	8
254	Non-Specific Abdominal Pain and Air Pollution: A Novel Association. <i>PLoS ONE</i> , 2012, 7, e47669.	2.5	57
255	Effect of potent endomorphin degradation blockers on analgesic and antidepressant-like responses in mice. <i>Neuropharmacology</i> , 2011, 61, 1229-1238.	4.1	10
256	Distribution, function and physiological role of melatonin in the lower gut. <i>World Journal of Gastroenterology</i> , 2011, 17, 3888.	3.3	173
257	Differential effects of salvinorin A on endotoxin-induced hypermotility and neurogenic ion transport in mouse ileum. <i>Neurogastroenterology and Motility</i> , 2011, 23, 583-e212.	3.0	10
258	Effect of 2,6-dimethyl-L-tyrosine (Dmt) on pharmacological activity of cyclic endomorphin-2 and morphiceptin analogs. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 6977-6981.	3.0	26
259	The role of morphine in regulation of cancer cell growth. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2011, 384, 221-230.	3.0	114
260	Synthesis and biological evaluation of new salvinorin A analogues incorporating natural amino acids. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 160-163.	2.2	10
261	Synthesis and opioid activity of novel 6-substituted-6-demethoxy-ethenomorphinans. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 3535-3542.	3.0	3
262	The Novel Endomorphin Degradation Blockers Tyr-Pro-D-CIPhe-Phe-NH ₂ (EMDB1) and Tyr-Pro-Ala-NH ₂ (EMDB2) Prolong Endomorphin ₂ Action in Rat Ileum <i>In Vitro</i> . <i>Chemical Biology and Drug Design</i> , 2010, 76, 77-81.	3.2	6
263	Design, Synthesis and Pharmacological Characterization of Endomorphin Analogues with Non-Cyclic Amino Acid Residues in Position 2. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010, 106, 106-113.	2.5	17
264	Development of Opioid Peptide Analogs for Pain Relief. <i>Current Pharmaceutical Design</i> , 2010, 16, 1126-1135.	1.9	42
265	Synthesis and biological evaluation of cyclic endomorphin-2 analogs. <i>Peptides</i> , 2010, 31, 339-345.	2.4	38
266	Synthesis and biological evaluation of novel peripherally active morphiceptin analogs. <i>Peptides</i> , 2010, 31, 1617-1624.	2.4	20
267	Novel endomorphin analogues with antagonist activity at the mu-opioid receptor in the gastrointestinal tract. <i>Regulatory Peptides</i> , 2010, 162, 109-114.	1.9	12
268	OPIOID ANTAGONIST-INDUCED REGULATION OF THE μ -OPIOID RECEPTOR EXPRESSION IN MCF-7 BREAST CANCER CELL LINE. <i>Endocrine Regulations</i> , 2009, 43, 23-28.	1.3	4
269	Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating μ -opioid and cannabinoid receptors. <i>Neurogastroenterology and Motility</i> , 2009, 21, 1326.	3.0	62
270	The Influence of Opioids on Urokinase Plasminogen Activator on Protein and mRNA Level in MCF-7 Breast Cancer Cell Line. <i>Chemical Biology and Drug Design</i> , 2009, 74, 390-396.	3.2	35

#	ARTICLE	IF	CITATIONS
271	Biological activity of endomorphin and [Dmt1]endomorphin analogs with six-membered proline surrogates in position 2. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 3789-3794.	3.0	29
272	Characterization and distribution of NKD, a receptor for <i>Drosophila</i> tachykinin-related peptide 6. <i>Peptides</i> , 2009, 30, 545-556.	2.4	78
273	Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction. <i>Drug News and Perspectives</i> , 2009, 22, 383.	1.5	19
274	Novel highly potent μ -opioid receptor antagonist based on endomorphin-2 structure. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1350-1353.	2.2	11
275	Synthesis and Biological Activity of Endomorphin-2 Analogs Incorporating Piperidine-3- or 4-Carboxylic Acids Instead of Proline in Position 2. <i>Chemical Biology and Drug Design</i> , 2008, 72, 91-94.	3.2	23
276	Identification of Endomorphin-1 and Endomorphin-2 Binding Sites in Human μ -Opioid Receptor by Antisense Oligonucleotide Strategy. <i>Chemical Biology and Drug Design</i> , 2008, 72, 507-512.	3.2	3
277	[Dmt1, d-1-Nal3]morphiceptin, a novel opioid peptide analog with high analgesic activity. <i>Peptides</i> , 2008, 29, 633-638.	2.4	11
278	Enzymatic degradation of endomorphins. <i>Peptides</i> , 2008, 29, 2066-2073.	2.4	84
279	Opioid-induced regulation of μ -opioid receptor gene expression in the MCF-7 breast cancer cell line. <i>Biochemistry and Cell Biology</i> , 2008, 86, 217-226.	2.0	27
280	Endomorphin Analogs. <i>Current Medicinal Chemistry</i> , 2007, 14, 3201-3208.	2.4	49
281	Antidepressant-Like Effect of Endomorphin-1 and Endomorphin-2 in Mice. <i>Neuropsychopharmacology</i> , 2007, 32, 813-821.	5.4	50
282	Functional comparison of two evolutionary conserved insect neurokinin-like receptors. <i>Peptides</i> , 2007, 28, 103-108.	2.4	26
283	The Endomorphin System and Its Evolving Neurophysiological Role. <i>Pharmacological Reviews</i> , 2007, 59, 88-123.	16.0	217
284	Synthesis and Characterization of Potent and Selective μ -Opioid Receptor Antagonists, [Dmt, d-2-Nal4]endomorphin-1 (Antanal-1) and [Dmt1, d-2-Nal4]endomorphin-2 (Antanal-2). <i>Journal of Medicinal Chemistry</i> , 2007, 50, 512-520.	6.4	40
285	μ -Opioid Receptor Ligands Lack Receptor Subtype Selectivity in the Aequorin Luminescence-based Calcium Assay. <i>Chemical Biology and Drug Design</i> , 2007, 70, 247-253.	3.2	6
286	[35S]GTP γ S binding stimulated by endomorphin-2 and morphiceptin analogs. <i>Biochemical and Biophysical Research Communications</i> , 2006, 345, 162-168.	2.1	5
287	[d-1-Nal4]endomorphin-2 is a potent μ -opioid receptor antagonist in the aequorin luminescence-based calcium assay. <i>Life Sciences</i> , 2006, 79, 1094-1099.	4.3	4
288	Enzymatic degradation studies of endomorphin-2 and its analogs containing N-methylated amino acids. <i>Peptides</i> , 2006, 27, 131-135.	2.4	41

#	ARTICLE	IF	CITATIONS
289	In vitro Characterization of Novel Peptide Inhibitors of Endomorphin-degrading Enzymes in the Rat Brain. <i>Chemical Biology and Drug Design</i> , 2006, 68, 173-175.	3.2	16
290	Characterization of Tachykinin-related Peptides from Different Insect Species on <i>Drosophila</i> Tachykinin Receptor-expressing Cell Line. <i>Chemical Biology and Drug Design</i> , 2006, 68, 284-286.	3.2	0
291	Functional Characterization of Opioid Receptor Ligands by Aequorin Luminescence-Based Calcium Assay. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 1150-1154.	2.5	24
292	Synthesis and biological activity of N-methylated analogs of endomorphin-2. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 6713-6717.	3.0	27
293	Binding of endomorphin-2 to mu-opioid receptors in experimental mouse mammary adenocarcinoma. <i>Chemical Biology and Drug Design</i> , 2005, 65, 459-464.	1.1	3
294	Novel endomorphin-2 analogs with mu-opioid receptor antagonist activity. <i>Chemical Biology and Drug Design</i> , 2005, 66, 125-131.	1.1	11
295	Characterization of antinociceptive activity of novel endomorphin-2 and morphiceptin analogs modified in the third position. <i>Biochemical Pharmacology</i> , 2005, 69, 179-185.	4.4	25
296	Synthesis and antinociceptive activity of cyclic endomorphin-2 and morphiceptin analogs. <i>Biochemical Pharmacology</i> , 2005, 71, 188-195.	4.4	25
297	Inhibition of trigemino-hypoglossal reflex in rats by oxytocin is mediated by μ and δ opioid receptors. <i>Brain Research</i> , 2005, 1035, 67-72.	2.2	21
298	Characterization of the [¹²⁵ I]endomorphin-2 binding sites in the MCF7 breast cancer cell line. <i>Peptides</i> , 2005, 26, 295-299.	2.4	12
299	Comparison of antagonist activity of spantide family at human neurokinin receptors measured by aequorin luminescence-based functional calcium assay. <i>Regulatory Peptides</i> , 2005, 131, 23-28.	1.9	15
300	Opioid Receptors and their Ligands. <i>Current Topics in Medicinal Chemistry</i> , 2004, 4, 1-17.	2.1	240
301	Opioid peptides in cancer. <i>Cancer and Metastasis Reviews</i> , 2004, 23, 351-366.	5.9	43
302	Opioid receptor binding and in vivo antinociceptive activity of position 3-substituted morphiceptin analogs. <i>Biochemical and Biophysical Research Communications</i> , 2004, 320, 531-536.	2.1	35
303	Binding of the new morphiceptin analogs to human MCF-7 breast cancer cells and their effect on growth. <i>Regulatory Peptides</i> , 2004, 120, 237-241.	1.9	9
304	Synthesis of novel morphiceptin analogues modified in position 3 and their binding to μ -opioid receptors in experimental mammary adenocarcinoma. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 3855-3860.	3.0	8
305	Synthesis of Target-Specific Radiolabeled Peptides for Diagnostic Imaging. <i>Bioconjugate Chemistry</i> , 2003, 14, 3-17.	3.6	124
306	Structure-activity Relationship, Conformation and Pharmacology Studies of Morphiceptin Analogues - Selective μ -Opioid Receptor Ligands. <i>Mini-Reviews in Medicinal Chemistry</i> , 2002, 2, 565-572.	2.4	13

#	ARTICLE	IF	CITATIONS
307	Effect of cerebral ventricles perfusion with morphiceptin and Met-enkephalin on trigemino-hypoglossal reflex in rats. <i>Journal of Physiology and Pharmacology</i> , 2002, 53, 741-50.	1.1	4
308	On the Way to Improve Diagnostic Marker Panel for Acute Appendicitis in Adults: the Role of Calprotectin. <i>Indian Journal of Surgery</i> , 0, , 1.	0.3	0